Navigation Links
Treatments have same target, different responses for lung cancer patients with genetic mutation

The gene mutation that identifies the lung cancer patients most likely to respond to the drug gefitinib (Iressa) is not associated with a response to the drug cetuximab (Erbitux), according to a new study published in the August 17 issue of the Journal of the National Cancer Institute. Both drugs target the same gene but through different mechanisms.

Some patients with non�small-cell lung cancer (NSCLC) have mutant versions of the epidermal growth factor receptor (EGFR). This protein activates signaling pathways involved with cell growth and survival. Previous studies have shown that small-molecule EGFR inhibitors such as gefitinib and erlotinib (Tarceva) work by blocking signals in the intracellular domain of EGFR--between the EGFR and the cell nucleus. Additionally, many NSCLC patients with mutations in this intracellular domain of EGFR appear to benefit from these drugs.

Toru Mukohara, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues decided to examine the effectiveness of another type of drug that targets EGFR--a monoclonal antibody called cetuximab, which is approved for the treatment of metastatic colorectal cancers that overexpress EGFR. Cetuximab targets EGFR by preventing its activation by extracellular signals, or signals occurring outside of the cell, as opposed to the intra-cellular signal blocking of drugs like gefitinib.

The researchers treated seven different NSCLC cell lines with cetuximab or gefitinib, and compared the drugs' effects on cell growth and cell death or apoptosis. They found that both drugs similarly inhibited the growth of the NSCLC cells containing the normal form of EGFR. However, gefitinib was more effective than cetuximab at inhibiting cell growth and increasing apoptosis in NSCLC cells with mutant EGFR.

The authors note that because these studies were carried out in cell lines, and not in humans, issues such as which drug has more toxicity or negative side effects are
'"/>

Source:Journal of the National Cancer Institute


Page: 1 2

Related biology news :

1. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
2. Effective Cancer Treatments Follow The Clock
3. Natural Killers Could Lead to New Hepatitis Treatments
4. Minimally Invasive Cancer Treatments Highlighted
5. Two designer drugs hit same lung cancer target, but only one is effective
6. Scientists discover how fish evolved to float at different sea depths
7. Genetics links whale to two different ocean basins
8. Stem cells bring fast direct improvement, without differentiation, in acute renal failure
9. Tiny roundworms telomeres help scientists to tease apart different types of aging
10. Tissue regeneration operates differently than expected
11. Human cerebellum and cortex age in very different ways

Post Your Comments:
(Date:11/26/2009)...impressive antlers, red deer have been caught in t...ntlers are much more than decorative. They are let...g. John Currey, from The University of York, UK, h...bone for over half a century and has become fascin...h a long-standing collaboration with Tomas Landete...
(Date:11/26/2009)...7 November 2009 What are the bare essentials of l...duce a cell that can survive on its own? Can we de...tand how an entire organism functions as a system?...sts in a partnership between the European Molecula..., and the Centre de Regulacio Genmica (CRG) in Bar...
(Date:11/25/2009)...eria don,t have easy lives. In addition to mammali... natural enemies called bacteriophages, viruses th... , Still, bacteria and another class of microor...e environments such as deep-sea volcanic vents) ma...ve a built-in defense system that helps protect th...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Researchers Uncover Why Turmeric Helps Heal 48078 1Interactive Video Games Offer Exercise Benefits 48076 1Interactive Video Games Offer Exercise Benefits 48076 2Interactive Video Games Offer Exercise Benefits 48076 3Golden Rainbow Celebrates Las Vegas Entertainment in 23rd Annual Ribbon of Life Production Show 48074 1Golden Rainbow Celebrates Las Vegas Entertainment in 23rd Annual Ribbon of Life Production Show 48074 2
...me genetically induced excess baggage may have hel...ts marine ancestors, according to a UBC study publ...ee to 10 centimetres long, stickleback fish origin...lakes and streams following the last ice age. Over...pan in evolutionary terms - freshwater stickleback...
... The advantage of using two eyes to see the world...r capacity to see in 3-D. Now, a new study from a ...uncovered a truly eye-opening advantage to binocul...ost animals fish, insects, reptiles, birds, rabbi...d environments like fields or plains, and they hav...
...tz will receive a special discretionary prize as p...ation (EMBO) Award for Communication in the Life S...tz,s long-term public communication activity on a ...is the author of the Springer book The Buzz About ...s of bees and bee colonies. , The Buzz about Bees...
Other Biology News:'Armored' fish study helps strengthen Darwin's natural selection theory 2Study says eyes evolved for X-Ray vision 2Study says eyes evolved for X-Ray vision 3Springer bee expert Juergen Tautz wins prize for public communication 2
(Date:11/24/2009)...ber24/PRNewswire-FirstCall/--deCODE,genetics,Inc.(...efrom,theNasdaqStockMarketthattradinginthecompany,...aForm25-NSEwillbefiledwiththe,SecuritiesandExchang...mlistingonNasdaq,unlessthecompanyfilesanappealtoth...ledsuchanappeal,which,willstaythesuspensionanddeli...
(Date:11/24/2009)...ber24/PRNewswire-FirstCall/--deCODE,genetics,Inc.(..."firstday"motionsbytheU.S.BankruptcyCourtfortheDis...eekfiledavoluntarypetitionfor,reliefunderChapter11...ourt. , TheordersissuedbytheBankruptcyCourtal...theChapter11proceedings.Inparticular,the,companyre...
(Date:11/24/2009)...ire-Asia/--ShanghaiBiolaxyannouncedthe,ChineseStat...nvestigationalnewdrugapplication(IND)foritsoralins...ntotreatdiabetes.ThisIND,approvalallowsBiolaxytoin...isadisordercharacteristicofhighbloodglucoseandpoor...nseveremicro-and,macro-vasculardiseases,lossofvisi...
(Date:11/24/2009)...hasbeenmetforpatientswithadvanced-stage,orrecurren...swire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ...mpanyfocusedonendocrinetherapyandoncology,todayann...argetedcytotoxicpeptideconjugate,AEZS-108(formerly...alcancer.Inapersonalizedhealthcareapproach,thestud...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...eclinical and Phase 1 safety studies, and plans fo...gn prostatic hyperplasia (BPH) are to be presented...LC, a biotechnology development company focused on...ad off the Bio(R) Business Forum in a presentation...usio has developed AUS-131, a pharmaceutical formu...
...Spherix Incorporated (Nasdaq: SPEX ), an innovat...ovider of technical and regulatory consulting serv...ceutical companies, today announced that it will e... Atlanta, Georgia on May 18-21, 2009. , , Spherix...Drug" booth will showcase their ongoing global pha...
...lts poster presentation Sunday, May 17, 8:15 a.m. ...ntation, Tuesday, May 19, 3:35 p.m. PDT - , , -...m. PDT - , , BRISBANE, Calif., May 14 InterMun...oral late-breaker presentation and two poster disc...onology programs will be presented at the 2009 Int...
Other Biology Technology:Ausio Pharmaceuticals to Present at Bio(R) 2009 2Spherix to Exhibit at the BIO 2009 International Convention 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5
BLOCK-iT Adenoviral RNAi Expression System from Invitrogen
pCC1BAC/plndigoBAC-5 Reverse Sequencing Primer from EPICENTRE Biotechnologies
...s ,,GenScript offers many antibody modific...ibody fragmentation. Labeling antibodies with biot...quantitation of the target molecule. In some assay...g (Fab) portion of the antibody. For these applica...
Protein Tyrosine Phosphatase 1B Colorimetric Assay Kit from Calbiochem
Biology Products: